Shandong Yuxin Pharmacy Co. Ltd.

To evaluate the bioequivalence of a single oral dose of rabeprazole sodium enteric-coated tablets (20 mg, Shandong Yuxin Pharmaceutical Co., Ltd.) to a reference formulation (Pariet®, 20 mg, licensed by Eisai Co., Ltd.) in healthy Chinese volunteers in the fed state.

To evaluate the bioequivalence of the test formulation of valacyclovir hydrochloride tablets (0.5 g, Shandong Yuxin Pharmaceutical Co., Ltd.) and the reference formulation (0.5 g, Valtrex®, The Wellcome Foundation Limited) after a single oral administration in healthy Chinese subjects in the fasting or fed state, and to evaluate the pharmacokinetic characteristics and safety of valacyclovir and its metabolite acyclovir.

To investigate the bioequivalence, pharmacokinetic characteristics and safety of a single oral dose of a test formulation of rivaroxaban tablets (20 mg, Shandong Yuxin Pharmaceutical Co., Ltd.) and a reference formulation of rivaroxaban tablets (20 mg, Xarelto®, Bayer AG) in fasting and fed states.